顺铂每周一次与每三周一次联合放疗治疗宫颈癌的疗效比较：一项荟萃分析结果
Concurrent weekly cisplatin versus triweekly cisplatin with radiotherapy in the treatment of cervical cancer: a meta-analysis result.
作者信息
Hu Yan, Cai Zhi-Qiang, Su Xiao-Yan
机构信息
Department of Oncology, The First People's Hospital of Jingzhou, Jingzhou, China.
出版信息
Asian Pac J Cancer Prev. 2012;13(9):4301-4. doi: 10.7314/apjcp.2012.13.9.4301.
AIMS
To evaluate the adverse effect and survival outcome of weekly and triweekly cisplatin with radiotherapy in treatment of cervical cancer.
METHODS
After an extensive literature search between 1995-2011,we analyzed 7 studies to compare weekly cisplatin and triweekly cisplatin combined radiotherapy.
RESULTS
Our analysis established that weekly cisplatin has a lower risk of hematologic toxicity than triweekly cisplatin with concurrent radiotherapy in the treatment of cervical cancer. However, there were no differences in progression free survival and overall survival between weekly cisplatin and triweekly cisplatin (p>0.05).
CONCLUSIONS
Weekly cisplatin combined with concurrent radiation has lower risk in hematologic toxicity than triweekly cisplatin, but does not improve survival. Triweekly cisplatin treatment has longer intervals and is therefore more convenient. Clinicians and patients can choose either weekly cisplatin or triweekly cisplatin combined radiotherapy for cervical cancer.
目的
评估每周一次和每三周一次顺铂联合放疗治疗宫颈癌的不良反应及生存结果。
方法
在对1995年至2011年间的大量文献进行检索后，我们分析了7项研究，以比较每周一次顺铂和每三周一次顺铂联合放疗的情况。
结果
我们的分析表明，在宫颈癌治疗中，每周一次顺铂与同期放疗联合使用时，血液学毒性的风险低于每三周一次顺铂。然而，每周一次顺铂和每三周一次顺铂之间的无进展生存期和总生存期并无差异（p>0.05）。
结论
每周一次顺铂联合同期放疗的血液学毒性风险低于每三周一次顺铂，但并未改善生存率。每三周一次顺铂治疗的间隔时间更长，因此更方便。临床医生和患者可以选择每周一次顺铂或每三周一次顺铂联合放疗来治疗宫颈癌。
Zotero 插件